16,794 Shares in West Pharmaceutical Services, Inc. $WST Acquired by Cibc World Market Inc.

Cibc World Market Inc. purchased a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 16,794 shares of the medical instruments supplier’s stock, valued at approximately $6,029,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of WST. Bank of Nova Scotia grew its stake in shares of West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after purchasing an additional 50,402 shares in the last quarter. Hsbc Holdings PLC lifted its holdings in West Pharmaceutical Services by 23.3% during the 4th quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after buying an additional 27,745 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of West Pharmaceutical Services by 100.2% during the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after acquiring an additional 104,924 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of West Pharmaceutical Services by 6.7% during the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock worth $32,826,000 after acquiring an additional 8,179 shares in the last quarter. Finally, Comerica Bank increased its holdings in shares of West Pharmaceutical Services by 31.8% in the 4th quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier’s stock valued at $15,599,000 after acquiring an additional 13,680 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 1.2%

WST opened at $348.97 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 52 week low of $223.83 and a 52 week high of $386.00. The business’s 50 day moving average is $349.44 and its two-hundred day moving average is $301.84. The firm has a market cap of $24.56 billion, a price-to-earnings ratio of 44.68, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period last year, the firm posted $1.84 earnings per share. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, research analysts predict that West Pharmaceutical Services, Inc. will post 8.93 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Wednesday, July 29th. West Pharmaceutical Services’s dividend payout ratio is presently 11.27%.

Analyst Upgrades and Downgrades

WST has been the topic of several research analyst reports. Morgan Stanley raised their target price on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 9th. KeyCorp increased their price target on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research note on Thursday, July 2nd. Citigroup raised their price objective on shares of West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Barclays upgraded shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $310.00 to $400.00 in a research report on Tuesday, June 9th. Finally, Evercore reaffirmed an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a research report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $368.08.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.